How to increase speed from project initiation to IND filing for CGT products
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Many early phase projects in the CGT space have extremely long lead times from project initiation to IND filing. This is due to the absence of standard technology platforms, a lack of clear understanding of the product quality attributes, and unclear regulatory requirements.
For many smaller companies, the inability to initiate clinical trials to gather safety and efficacy data impacts survival in a capital constraint economy. For bigger companies this results in increased cost, decreased revenue opportunities, and an inability to stay at the forefront of the industry and meet current and future demands. Finally and most crucially, there are patients waiting at the end of the process.
Attendees will learn about:
- Common reasons for early phase CGT project delays
- Creative ways to overcome these challenges from technical, quality, and regulatory points of view
- Current regulatory trends in cell and gene therapy
- Regulatory services for lentiviral vectors and cell therapy
SPEAKERS